Pathological AT1R-B2R Protein Aggregation and Preeclampsia
Preeclampsia is one of the most frequent and severe complications of pregnancy. Symptoms of preeclampsia usually occur after 20 weeks of pregnancy and include hypertension and kidney dysfunction with proteinuria. Up to now, delivery of the infant has been the most effective and life-saving treatment...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/10/10/2609 |
| _version_ | 1797514984509407232 |
|---|---|
| author | Ursula Quitterer Said AbdAlla |
| author_facet | Ursula Quitterer Said AbdAlla |
| author_sort | Ursula Quitterer |
| collection | DOAJ |
| description | Preeclampsia is one of the most frequent and severe complications of pregnancy. Symptoms of preeclampsia usually occur after 20 weeks of pregnancy and include hypertension and kidney dysfunction with proteinuria. Up to now, delivery of the infant has been the most effective and life-saving treatment to alleviate symptoms of preeclampsia because a causative treatment does not exist, which could prolong a pregnancy complicated with preeclampsia. Preeclampsia is a complex medical condition, which is attributed to a variety of different risk factors and causes. Risk factors account for insufficient placentation and impaired vasculogenesis and finally culminate in this life-threatening condition of pregnancy. Despite progress, many pathomechanisms and causes of preeclampsia are still incompletely understood. In recent years, it was found that excessive protein complex formation between G-protein-coupled receptors is a common sign of preeclampsia. Specifically, the aberrant heteromerization of two vasoactive G-protein-coupled receptors (GPCRs), the angiotensin II AT1 receptor and the bradykinin B2 receptor, is a causative factor of preeclampsia symptoms. Based on this knowledge, inhibition of abnormal GPCR protein complex formation is an experimental treatment approach of preeclampsia. This review summarizes the impact of pathological GPCR protein aggregation on symptoms of preeclampsia and delineates potential new therapeutic targets. |
| first_indexed | 2024-03-10T06:39:16Z |
| format | Article |
| id | doaj.art-2d1e6eb9169d4d1fbea9a3b3f3c94f76 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T06:39:16Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-2d1e6eb9169d4d1fbea9a3b3f3c94f762023-11-22T17:46:20ZengMDPI AGCells2073-44092021-10-011010260910.3390/cells10102609Pathological AT1R-B2R Protein Aggregation and PreeclampsiaUrsula Quitterer0Said AbdAlla1Molecular Pharmacology, Department of Chemistry and Applied Biosciences, ETH Zurich, Winterthurerstrasse 190, CH-8057 Zürich, SwitzerlandMolecular Pharmacology, Department of Chemistry and Applied Biosciences, ETH Zurich, Winterthurerstrasse 190, CH-8057 Zürich, SwitzerlandPreeclampsia is one of the most frequent and severe complications of pregnancy. Symptoms of preeclampsia usually occur after 20 weeks of pregnancy and include hypertension and kidney dysfunction with proteinuria. Up to now, delivery of the infant has been the most effective and life-saving treatment to alleviate symptoms of preeclampsia because a causative treatment does not exist, which could prolong a pregnancy complicated with preeclampsia. Preeclampsia is a complex medical condition, which is attributed to a variety of different risk factors and causes. Risk factors account for insufficient placentation and impaired vasculogenesis and finally culminate in this life-threatening condition of pregnancy. Despite progress, many pathomechanisms and causes of preeclampsia are still incompletely understood. In recent years, it was found that excessive protein complex formation between G-protein-coupled receptors is a common sign of preeclampsia. Specifically, the aberrant heteromerization of two vasoactive G-protein-coupled receptors (GPCRs), the angiotensin II AT1 receptor and the bradykinin B2 receptor, is a causative factor of preeclampsia symptoms. Based on this knowledge, inhibition of abnormal GPCR protein complex formation is an experimental treatment approach of preeclampsia. This review summarizes the impact of pathological GPCR protein aggregation on symptoms of preeclampsia and delineates potential new therapeutic targets.https://www.mdpi.com/2073-4409/10/10/2609preeclampsiaangiotensin IIAGTR1 (angiotensin II receptor type 1)bradykininBDKRB2 (bradykinin receptor B2)AT1R-B2R heteromer (protein complex formed of AT1R-B2R) |
| spellingShingle | Ursula Quitterer Said AbdAlla Pathological AT1R-B2R Protein Aggregation and Preeclampsia Cells preeclampsia angiotensin II AGTR1 (angiotensin II receptor type 1) bradykinin BDKRB2 (bradykinin receptor B2) AT1R-B2R heteromer (protein complex formed of AT1R-B2R) |
| title | Pathological AT1R-B2R Protein Aggregation and Preeclampsia |
| title_full | Pathological AT1R-B2R Protein Aggregation and Preeclampsia |
| title_fullStr | Pathological AT1R-B2R Protein Aggregation and Preeclampsia |
| title_full_unstemmed | Pathological AT1R-B2R Protein Aggregation and Preeclampsia |
| title_short | Pathological AT1R-B2R Protein Aggregation and Preeclampsia |
| title_sort | pathological at1r b2r protein aggregation and preeclampsia |
| topic | preeclampsia angiotensin II AGTR1 (angiotensin II receptor type 1) bradykinin BDKRB2 (bradykinin receptor B2) AT1R-B2R heteromer (protein complex formed of AT1R-B2R) |
| url | https://www.mdpi.com/2073-4409/10/10/2609 |
| work_keys_str_mv | AT ursulaquitterer pathologicalat1rb2rproteinaggregationandpreeclampsia AT saidabdalla pathologicalat1rb2rproteinaggregationandpreeclampsia |